Abstract:Importance There are reported benefits from vitrectomy for diabetic macular edema (DME); however, data precede anti–vascular endothelial growth therapy (VEGF) therapy, supporting a need to assess the current role of vitrectomy. Objective To determine rates of recruitment and efficacy outcomes of vitrectomy plus internal limiting membrane (ILM) peeling adjunctive to treat-and-extend (T&E) anti-VEGF injections for diabetic macular edema (DME). Design, Setting, and Participants This was a single-masked, multicenter randomized clinical trial at 21 sites in the United Kingdom from June 2018 to January 2021, evaluating single eyes of treatment-naive patients with symptomatic vision loss from DME for less than 1 year. Inclusion criteria were best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score greater than 35 (approximate Snellen equivalent, 20/200 or better) and central subfield thickness (CST) greater than 350 μm after 3 monthly intravitreal injections of ranibizumab or aflibercept. Data analysis was performed in July 2023. Interventions Patients were randomized 1:1 into vitrectomy plus standard care or standard care alone and further stratified into groups with vs without vitreomacular interface abnormality. Both groups received a T&E anti-VEGF injection regimen with aflibercept, 2 mg, or ranibizumab, 0.5 mg. The vitrectomy group additionally underwent pars plana vitrectomy with epiretinal membrane or ILM peel within 1 month of randomization. Main Outcomes and Measures Rate of recruitment and distance BCVA. Secondary outcome measures were CST, change in BCVA and CST, number of injections, rate of completed follow-up, and withdrawal rate. Results Over 32 months, 47 of a planned 100 patients were enrolled; 42 (89%; mean [SD] age, 63 [11] years; 26 [62%] male) completed 12-month follow-up visits. Baseline characteristics appeared comparable between the control (n = 23; mean [SD] age, 66 [10] years) and vitrectomy (n = 24; mean [SD] age, 62 [12] years) groups. No difference in 12-month BCVA was noted between groups, with a 12-month median (IQR) BCVA letter score of 73 (65-77) letters (Snellen equivalent, 20/40) in the control group vs 77 (67-81) letters (Snellen equivalent, 20/32) in the vitrectomy group (difference, 4 letters; 95% CI, −8 to 2; P = .24). There was no difference in BCVA change from baseline (median [IQR], −1 [−3 to 2] letters for the control group vs −2 [−8 to 2] letters for the vitrectomy group; difference, 1 letter; 95% CI, −5 to 7; P = .85). No difference was found in CST changes (median [IQR], −94 [−122 to 9] μm for the control group vs −32 [−48 to 25] μm for the vitrectomy group; difference, 62 μm; 95% CI, −110 to 11; P = .11). Conclusions and Relevance Enrollment goals could not be attained. However, with 47 participants, evidence did not support a clinical benefit of vitrectomy plus ILM peeling as an adjunct to a T&E regimen of anti-VEGF therapy for DME. Trial Registration isrctn.org Identifier:ISRCTN59902040

COMBINATION OF VITRECTOMY AND INTENTIONAL MACULAR DETACHMENT IS ASSOCIATED WITH A FASTER EDEMATOUS REGRESSION THAN VITRECTOMY ALONE IN THE TREATMENT OF REFRACTORY DIABETIC MACULAR EDEMA

Retinal Microstructure Based on Optical Coherence Tomography Predicts Visual Prognosis in Diabetic Macular Edema with Extended Intraretinal Cysts and Subretinal Fluid.

The Treatment of Vitrectomy Combined with Internal Limiting Membrane Peeling in Diabetic Macular Edema

Anti-VEGF Combined with Ocular Corticosteroids Therapy Versus Anti-Vegf Monotherapy for Diabetic Macular Edema Focusing on Drugs Injection Times and Confounding Factors of Pseudophakic Eyes: A Systematic Review and Meta-Analysis.

Efficacy Of Internal Limiting Membrane Peeling For Diabetic Macular Edema After Preoperative Anti-Vascular Endothelial Growth Factor Injection

The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema

The role and efficacy of vitrectomy for the management of refractory diabetic macular edema: Systematic review and meta-analysis

Effects of vitrectomy combined with internal limiting membrane peeling in patients with diabetic macular edema

Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema

Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice.

Clinical efficacy of different treatment for refractory diabetic macular edema

Efficacy and Safety of Vitrectomy with Internal Limiting Membrane Peeling for Diabetic Macular Edema: a Meta-analysis.

Internal Limiting Peeling in Conjunction with Subretinal Injection of a Balanced Salt Solution in the Macular Region to Treat Refractory Diabetic Macular Edema

Combined methods for the treatment of refractory diabetic macular edema

Efficacy of the combination of intravitreal aflibercept and triamcinolone injections in treatment of diabetic macular edema

The Conversion of Macular Function in Diabetic Macular Edema after Vitreous Surgery

Clinical Effects And Safety Of Treating Diabetic Macular Edema With Intravitreal Injection Of Ranibizumab Combined With Retinal Photocoagulation

Combination of Internal Limiting Membrane Peeling and Endophotocoagulation for Retinal Detachment Related to High Myopia in Patients with Macular Hole

Assessment of Macular Function by Multifocal Electroretinogram in Diabetic Macular Edema Before and after Vitrectomy

Intravitreal lucentis injection combined with macular grid photocoagulation for diabetic macular edema

Efficacy and safety of intravitreal dexamethasone implant in diabetic macular edema patients with and without prior vitrectomy: a retrospective cohort study